CN107002113A - 脂肪肝病的生物标志物和其使用方法 - Google Patents

脂肪肝病的生物标志物和其使用方法 Download PDF

Info

Publication number
CN107002113A
CN107002113A CN201580063349.2A CN201580063349A CN107002113A CN 107002113 A CN107002113 A CN 107002113A CN 201580063349 A CN201580063349 A CN 201580063349A CN 107002113 A CN107002113 A CN 107002113A
Authority
CN
China
Prior art keywords
biomarkers
subject
sample
level
liver diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580063349.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·佩里肖恩
L·N·贝尔
J·伍尔夫
U·T·恩格扬
S·M·瓦特金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of CN107002113A publication Critical patent/CN107002113A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580063349.2A 2014-11-19 2015-11-18 脂肪肝病的生物标志物和其使用方法 Pending CN107002113A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462081903P 2014-11-19 2014-11-19
US62/081,903 2014-11-19
US201562141494P 2015-04-01 2015-04-01
US62/141,494 2015-04-01
PCT/US2015/061215 WO2016081534A1 (en) 2014-11-19 2015-11-18 Biomarkers for fatty liver disease and methods using the same

Publications (1)

Publication Number Publication Date
CN107002113A true CN107002113A (zh) 2017-08-01

Family

ID=56014479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063349.2A Pending CN107002113A (zh) 2014-11-19 2015-11-18 脂肪肝病的生物标志物和其使用方法

Country Status (5)

Country Link
US (1) US20170370954A1 (cg-RX-API-DMAC7.html)
EP (1) EP3221463A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018502286A (cg-RX-API-DMAC7.html)
CN (1) CN107002113A (cg-RX-API-DMAC7.html)
WO (1) WO2016081534A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721462B (zh) * 2018-09-26 2021-03-11 日商島津製作所股份有限公司 非酒精性脂肪肝疾病的檢測方法、非酒精性脂肪肝疾病檢測用試劑盒和非酒精性脂肪肝疾病檢測用生物標記
CN112712896A (zh) * 2021-03-26 2021-04-27 深圳市绘云生物科技有限公司 用于检测非酒精性脂肪性肝病状态的诊断装置
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
CN113195732A (zh) * 2018-12-19 2021-07-30 阿斯利康(瑞典)有限公司 Pnpla3表达的生物标记
WO2023097510A1 (zh) * 2021-11-30 2023-06-08 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120375A1 (en) * 2016-01-05 2017-07-13 Wizr Llc Video event detection and notification
EP3465218A4 (en) * 2016-05-29 2020-06-17 Human Metabolomics Institute, Inc. BIOMARKERS RELATED TO HEPATIC DISEASES AND METHODS OF USE
ES2953498T3 (es) 2016-06-02 2023-11-13 Metabolon Inc Método de espectrometría de masas para la detección y cuantificación de metabolitos
WO2018007422A1 (en) * 2016-07-05 2018-01-11 One Way Liver,S.L. Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP3267199A1 (en) * 2016-07-06 2018-01-10 One Way Liver S.L. Diagnostic methods based on lipid profiles
WO2019097089A1 (en) 2017-11-20 2019-05-23 Zora Biosciences Oy Methods for prediction and early detection of diabetes
EP3502703A1 (en) 2017-12-22 2019-06-26 Metanomics Health GmbH Method for the assessment of nafld
US11536726B2 (en) 2018-04-04 2022-12-27 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of liver function metabolites
US20210349103A1 (en) * 2018-06-18 2021-11-11 Duke University Metabolic biomarkers of nafld/nash and related disease phenotypes and methods of using same
JP7029139B2 (ja) * 2018-08-23 2022-03-03 デンカ株式会社 非アルコール性脂肪性肝炎の検出を補助する方法
JP6592638B1 (ja) * 2018-08-30 2019-10-16 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
KR102105880B1 (ko) * 2018-10-26 2020-04-29 서울대학교병원 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법
JP6592627B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP6592628B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
KR102280261B1 (ko) * 2019-07-16 2021-07-20 이화여자대학교 산학협력단 대사체 분석을 이용한 간질환의 진단 방법
CN110507670B (zh) * 2019-09-24 2023-04-07 江西天元药业有限公司 精制熊胆粉及预防治疗肝病肝纤维化改善肝功能的用途
US20230064246A1 (en) * 2019-11-05 2023-03-02 Beth Israel Deaconess Medical Center, Inc. Diagnosis and treatment of nafld and liver fibrosis
WO2021157631A1 (ja) * 2020-02-04 2021-08-12 デンカ株式会社 非アルコール性脂肪肝炎の検出を補助する方法
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
US20240053355A1 (en) * 2021-03-18 2024-02-15 Complete Omics Inc. Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー
WO2024237258A1 (ja) * 2023-05-17 2024-11-21 株式会社島津製作所 非アルコール性脂肪肝疾患の識別方法、および、バイオマーカー
CN121100279A (zh) * 2023-05-17 2025-12-09 株式会社岛津制作所 非酒精性脂肪性肝病的发生风险评价方法和生物标志物
WO2025008465A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a biomarker for determining the child-pugh class into which an individual is to be classified
WO2025008466A1 (en) 2023-07-06 2025-01-09 Numares Ag Use of a biomarker for determining the risk of an individual to have hepatic encephalopathy
WO2025008464A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker or a marker set for determining the risk of an individual to have ascites
WO2025008467A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker or a marker set for determining the risk of an individual to have a reduced liver function
EP4653872A1 (en) * 2024-05-22 2025-11-26 Cristóbal Manuel Richart Jurado A set of biomarkers and an in vitro method for the diagnosis of metabolic dysfunction-associated steatohepatitis (mash)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100279956A1 (en) * 2007-11-02 2010-11-04 Mc Creedy Jr Bruce J Biomarkers For Fatty Liver Disease And Methods Using The Same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2005052575A1 (en) * 2003-11-28 2005-06-09 Pfizer Limited Molecular markers of oxidative stress
US7856319B2 (en) * 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers
US7561975B2 (en) 2006-03-21 2009-07-14 Metabolon, Inc. System, method, and computer program product for analyzing spectrometry data to identify and quantify individual components in a sample
US7883904B2 (en) * 2006-05-19 2011-02-08 The Cleveland Clinic Foundation Detection and monitoring of liver damage
WO2010091290A1 (en) * 2009-02-06 2010-08-12 Metabolon, Inc. Determination of the liver toxicity of an agent
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
EP2513653A1 (en) * 2009-10-09 2012-10-24 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
CA2799032A1 (en) * 2010-06-10 2012-01-05 Metanomics Health Gmbh Methods to diagnose liver diseases
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
EP2776832A4 (en) * 2011-11-11 2015-06-03 Metabolon Inc BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE
US10634686B2 (en) * 2013-09-23 2020-04-28 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers related to organ function
WO2015157407A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100279956A1 (en) * 2007-11-02 2010-11-04 Mc Creedy Jr Bruce J Biomarkers For Fatty Liver Disease And Methods Using The Same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721462B (zh) * 2018-09-26 2021-03-11 日商島津製作所股份有限公司 非酒精性脂肪肝疾病的檢測方法、非酒精性脂肪肝疾病檢測用試劑盒和非酒精性脂肪肝疾病檢測用生物標記
CN113195732A (zh) * 2018-12-19 2021-07-30 阿斯利康(瑞典)有限公司 Pnpla3表达的生物标记
CN112712896A (zh) * 2021-03-26 2021-04-27 深圳市绘云生物科技有限公司 用于检测非酒精性脂肪性肝病状态的诊断装置
CN112712896B (zh) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
WO2023097510A1 (zh) * 2021-11-30 2023-06-08 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用

Also Published As

Publication number Publication date
WO2016081534A1 (en) 2016-05-26
US20170370954A1 (en) 2017-12-28
EP3221463A4 (en) 2018-07-25
EP3221463A1 (en) 2017-09-27
JP2018502286A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
CN107002113A (zh) 脂肪肝病的生物标志物和其使用方法
US9977034B2 (en) Biomarkers for fatty liver disease and methods using the same
Zhou et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites
EP3129909B1 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
Reis et al. Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease
EP2480895B1 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
US10534001B2 (en) Methods for detecting ovarian cancer
WO2013038369A1 (en) Means and methods for assessing kidney toxicity
WO2018007422A1 (en) Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP2904397B1 (en) Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
US8563318B2 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
CN113711047B (zh) 有关非酒精性脂肪性肝病的组织学严重程度诊断或预后测量的信息提供方法
HK40049279A (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
HK1216189B (en) Biomarkers for fatty liver disease and methods using the same
US20210405054A1 (en) Methods for detecting ovarian cancer
AU2012310100A1 (en) Means and methods for assessing kidney toxicity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

WD01 Invention patent application deemed withdrawn after publication